Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

The study proposes the immune system as a major regulator of blood sugar. The functions of hormones like insulin and glucagon ...

Israeli and American researchers uncovered the role of a specific enzyme in managing blood sugar levels in a study that opens up new therapeutic possibilities for people with type 2 diabetes. Type 2 ...

When we think about the immune system, we usually associate it with fighting infections. However, a study published in Science by the Champalimaud Foundation reveals a surprising new role.

Findings suggest targeting neuro-immune pathway could lead to strategies for managing diabetes, obesity or some types of ...